Expression of Shh and/or Bcl2 can be used as markers to identify non-compliant patients and CML-variants who are likely to demonstrate this mutation-independent Imatinib resistance. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.